Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/29/26
Biogen Walloped Wall Street's First Quarter Views; Here's What HappenedInvestors Business Daily • 04/29/26
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?Zacks Investment Research • 04/24/26
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to DeclineZacks Investment Research • 04/22/26
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?24/7 Wall Street • 04/22/26
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock UpZacks Investment Research • 04/21/26
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLSBusiness Wire • 04/20/26
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?24/7 Wall Street • 04/20/26
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ BiopharmaReuters • 04/20/26
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China RegionGlobeNewsWire • 04/20/26
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.Market Watch • 04/18/26
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time HighZacks Investment Research • 04/16/26
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?The Motley Fool • 04/16/26
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO PlatformBusiness Wire • 04/07/26